See more : Jindal Leasefin Limited (JLL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of RespireRx Pharmaceuticals Inc. (RSPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RespireRx Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BBGI Public Company Limited (BBGI.BK) Income Statement Analysis – Financial Results
- Encompass Health Corporation (EHC) Income Statement Analysis – Financial Results
- Bradda Head Lithium Limited (BHLIF) Income Statement Analysis – Financial Results
- DATA Communications Management Corp. (DCMDF) Income Statement Analysis – Financial Results
- Avacta Group Plc (AVCT.L) Income Statement Analysis – Financial Results
RespireRx Pharmaceuticals Inc. (RSPI)
About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.92K | 61.67K | 0.00 | 48.31K | 3.11M | 10.47M | 11.00K | 0.00 | 25.00K | 1.18M | 2.58M | 6.97B | 5.23M | 6.43M | 4.44M | 5.51M | 3.15M | 130.00K | 0.00 | 0.00 | 100.00K | 100.00K | 2.60M | 1.00M | 100.00K | 100.00K | 100.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.17K | 6.95K | 1.71K | 591.77 | 206.91 | 826.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -172.76K | 0.00 | 0.00 | 0.00 | 0.00 | 4.10M | 2.80M | 1.80M | 2.10M | 1.80M | 2.40M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.17K | -6.95K | 85.21K | 61.08K | -206.91 | 47.48K | 3.11M | 10.47M | 11.00K | 0.00 | 25.00K | 1.18M | 2.58M | 6.97B | 5.23M | 6.43M | 4.44M | 5.68M | 3.15M | 130.00K | 0.00 | 0.00 | -4.00M | -2.70M | 800.00K | -1.10M | -1.70M | -2.30M | 100.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 98.04% | 99.04% | 0.00% | 98.29% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 103.14% | 100.00% | 100.00% | 0.00% | 0.00% | -4,000.00% | -2,700.00% | 30.77% | -110.00% | -1,700.00% | -2,300.00% | 100.00% | 0.00% |
| Research & Development | 429.53K | 702.04K | 638.28K | 599.33K | 688.29K | 1.73M | 3.18M | 1.71M | 591.77K | 206.91K | 826.70K | 2.19M | 3.74M | 4.60M | 10.78M | 9.33M | 13.26M | 11.18M | 6.12B | 3.80M | 5.04M | 4.41M | 3.90M | 3.38M | 4.01M | 3.38M | 2.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 110.00K |
| General & Administrative | 1.15M | 1.86M | 2.68M | 1.14M | 1.49M | 2.52M | 5.30M | 3.62M | 3.82M | 932.97K | 1.95M | 3.19M | 4.55M | 3.74M | 4.26M | 4.32M | 3.38B | 3.39B | 2.29B | 2.62B | 2.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 220.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -397.00 | -82.00 | -3.37B | -3.39B | 0.00 | -2.62B | -2.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.15M | 1.86M | 2.68M | 1.14M | 1.49M | 2.52M | 5.30M | 3.62M | 3.82M | 932.97K | 1.95M | 3.19M | 4.55M | 3.74M | 4.26M | 4.32M | 4.62M | 3.56M | 2.29B | 2.62M | 2.44M | 2.43M | 1.81M | 1.40M | 1.58M | 1.71M | 1.64M | 2.90M | 2.00M | 1.40M | 1.30M | 900.00K | 0.00 | 1.30M | 220.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.62M | 1.11B | 0.00 | 0.00 | 0.00 | 172.76K | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 0.00 | 10.00K |
| Operating Expenses | 1.58M | 2.56M | 3.32M | 1.74M | 2.18M | 4.25M | 8.47M | 5.33M | 4.42M | 1.14M | 2.77M | 5.38M | 8.29M | 8.33M | 15.04M | 13.65M | 17.88M | 14.74M | 9.51B | 6.42M | 7.49M | 6.84M | 5.88M | 4.78M | 5.59M | 5.09M | 4.32M | 3.10M | 2.20M | 1.60M | 1.40M | 1.00M | 100.00K | 1.30M | 340.00K |
| Cost & Expenses | 1.58M | 2.56M | 3.32M | 1.74M | 2.18M | 4.25M | 8.47M | 5.33M | 4.42M | 1.14M | 2.77M | 5.38M | 8.29M | 8.33M | 15.04M | 13.65M | 17.88M | 14.74M | 9.51B | 6.42M | 7.49M | 6.84M | 5.71M | 4.78M | 5.59M | 5.09M | 4.32M | 7.20M | 5.00M | 3.40M | 3.50M | 2.80M | 2.50M | 1.30M | 340.00K |
| Interest Income | 603.82 | 724.77 | 545.68 | 404.66 | 0.00 | 0.00 | 8.00 | 9.00 | 0.00 | 0.00 | 92.00 | 1.86K | -8.50K | 16.58K | 443.06K | 678.05K | 645.82K | 637.37K | 0.00 | 0.00 | 72.14K | 254.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 603.82K | 724.77K | 545.68K | 404.66K | 136.24K | 102.23K | 586.35K | 902.70K | 117.31K | 56.34K | 196.98K | 4.02K | 1.63M | -8.44M | -14.60M | -12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.93M | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.00K |
| Depreciation & Amortization | 80.45K | 2.56M | 3.32M | 1.74M | 5.17K | 5.17K | 6.95K | 7.12K | 1.66K | -7.22K | 115.86K | 106.97K | 112.48K | 186.94K | 164.89K | 126.85K | 110.79K | 125.98K | 0.00 | 155.85K | 153.18K | 149.48K | 172.76K | 197.66K | 201.66K | 198.06K | 230.22K | -200.00K | -200.00K | -200.00K | -100.00K | 100.00K | 100.00K | 20.00K | 50.00K |
| EBITDA | -1.50M | -963.75K | -2.43M | -378.53K | -2.46M | -4.24M | -8.46M | -5.05M | -2.59M | -1.14M | -7.26M | -2.15M | 2.29M | -8.25M | -14.43M | -12.84M | -15.94M | -11.50M | -2.54B | -1.03M | -901.60K | -2.25M | -30.01K | -1.43M | -5.26M | -4.89M | -4.09M | -7.10M | -5.00M | -600.00K | -2.50M | -2.60M | -2.30M | -1.20M | -290.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,020.17% | -7,057.06% | 0.00% | -5,400.72% | -69.18% | 21.99% | -72,951.27% | 0.00% | -54,081.46% | -1,408.95% | -463.68% | -36.43% | -19.75% | -14.02% | -50.61% | -0.54% | -45.45% | -4,046.29% | 0.00% | 0.00% | -7,100.00% | -5,000.00% | -23.08% | -250.00% | -2,800.00% | -2,500.00% | -1,300.00% | 0.00% |
| Operating Income | -1.58M | -2.56M | -3.32M | -1.74M | -2.18M | -4.25M | -8.47M | -5.24M | -4.35M | -1.14M | -7.33M | -2.26M | 2.18M | -8.33M | -15.04M | -13.65M | -16.70M | -12.16M | -2.54B | -1.19M | -1.05M | -2.40M | -202.77K | -1.63M | -5.46M | -5.09M | -4.32M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.22M | -340.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,028.37% | -7,059.75% | 0.00% | -15,177.09% | -72.62% | 20.83% | -75,770.52% | 0.00% | -54,588.86% | -1,418.36% | -471.78% | -36.43% | -22.73% | -16.40% | -53.98% | -3.68% | -51.72% | -4,201.41% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,220.00% | 0.00% |
| Total Other Income/Expenses | -523.37K | -585.71K | -986.08K | -378.53K | -415.27K | -44.07K | -757.87K | -722.28K | 1.65M | -63.56K | -240.34K | 6.95K | -553.30K | -106.60K | 443.06K | 678.05K | 645.82K | 554.38K | 0.00 | 14.51K | 72.14K | 2.40M | 5.37K | 8.48K | 203.88K | 155.62K | 163.06K | 200.00K | 300.00K | 0.00 | 100.00K | 200.00K | 200.00K | 100.00K | 20.00K |
| Income Before Tax | -2.10M | -3.14M | -4.30M | -2.12M | -2.59M | -4.29M | -9.23M | -5.96M | -2.71M | -1.20M | -7.57M | -2.25M | 1.63M | -8.44M | -14.60M | -12.97M | -16.05M | -11.61M | 0.00 | -1.17M | -982.64K | -2.67M | -197.40K | -1.62M | -5.26M | -4.93M | -4.16M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.20M | -320.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,859.37% | -4,390.57% | 0.00% | -15,674.60% | -72.40% | 15.55% | -76,739.58% | 0.00% | -51,876.65% | -1,363.51% | -450.28% | 0.00% | -22.46% | -15.28% | -60.17% | -3.58% | -51.45% | -4,044.58% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,200.00% | 0.00% |
| Income Tax Expense | -80.45K | 724.77K | 545.68K | 404.66K | 279.02K | 44.07K | 757.87K | 722.28K | -1.65M | 7.22K | 4.85M | 2.25M | -1.63M | 8.44M | 14.60M | 12.97M | 16.05M | 11.61M | 0.00 | 1.17M | 982.64K | 2.67M | 197.40K | 1.62M | 5.26M | 4.93M | 4.16M | 6.80M | 4.70M | 800.00K | 2.40M | 2.60M | 2.20M | 1.20M | -50.00K |
| Net Income | -3.97M | -3.87M | -4.85M | -2.52M | -2.59M | -4.29M | -9.23M | -5.96M | -2.71M | -1.20M | -7.57M | -2.25M | 1.63M | -8.44M | -14.60M | -12.97M | -16.05M | -11.61M | 0.00 | -1.17M | -982.64K | -2.67M | -197.40K | -1.62M | -5.26M | -4.93M | -4.16M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.20M | -270.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,859.37% | -4,390.57% | 0.00% | -15,674.60% | -72.40% | 15.55% | -76,739.58% | 0.00% | -51,876.65% | -1,363.51% | -450.28% | 0.00% | -22.46% | -15.28% | -60.17% | -3.58% | -51.45% | -4,044.58% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,200.00% | 0.00% |
| EPS | -0.04 | -0.04 | -0.19 | -6.45 | -7.73 | -17.75 | -49.51 | -50.40 | -45.65 | -27.11 | -226.92 | -91.62 | 65.00 | -491.81 | -997.19 | -1.00K | -1.52K | -1.15K | 0.00 | -226.37 | -191.10 | -523.36 | -40.62 | -393.08 | -1.78K | -1.94K | -2.07K | -3.67K | -3.09K | -779.73 | -2.56K | -3.21K | -2.74K | -1.93K | -27.00 |
| EPS Diluted | -0.04 | -0.04 | -0.19 | -6.45 | -7.73 | -17.75 | -49.51 | -50.40 | -45.65 | -27.11 | -226.92 | -91.62 | 65.00 | -491.81 | -997.19 | -1.00K | -1.52K | -1.15K | 0.00 | -226.37 | -177.31 | -523.36 | -40.62 | -393.08 | -1.78K | -1.94K | -2.07K | -3.67K | -3.09K | -779.73 | -2.56K | -3.21K | -2.74K | -1.93K | -27.00 |
| Weighted Avg Shares Out | 111.32M | 88.35M | 25.86M | 390.85K | 335.11K | 241.83K | 186.40K | 118.29K | 59.31K | 44.32K | 33.37K | 24.61K | 22.67K | 17.16K | 14.64K | 12.96K | 10.57K | 10.05K | 7.13K | 5.19K | 5.14K | 5.11K | 4.86K | 4.13K | 2.95K | 2.54K | 2.01K | 1.85K | 1.52K | 1.03K | 937.00 | 810.00 | 802.00 | 621.00 | 10.00K |
| Weighted Avg Shares Out (Dil) | 111.32M | 88.35M | 25.86M | 390.85K | 335.11K | 241.83K | 186.40K | 118.29K | 59.31K | 44.32K | 33.37K | 24.61K | 22.67K | 17.16K | 14.64K | 12.96K | 10.57K | 10.05K | 7.13K | 5.19K | 5.54K | 5.11K | 4.86K | 4.13K | 2.95K | 2.54K | 2.01K | 1.85K | 1.52K | 1.03K | 937.00 | 810.00 | 802.00 | 621.00 | 10.00K |
RespireRx Pharmaceuticals Inc is advancing an innovative portfolio targeting poorly or unmet patient need
RespireRx Pharmaceuticals (OTCQB:RSPI) Inc is a tiny company with huge ambitions as it advances a portfolio of innovative drugs to combat neurological and psychiatric conditions, which affect millions around the world. With a market cap of US$1.7 million, it is...
RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™
Glen Rock, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), with a mission to discover and develop innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased...
RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference
Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling,...
Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the OTCQB Venture Market, effective with opening of...
Source: https://incomestatements.info
Category: Stock Reports